Resource Summary Report

Generated by RRID on Sep 2, 2026

PaTu 8988t

RRID:CVCL_1847
Type: Cell Line

Proper Citation

RRID:CVCL_1847

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1847

Proper Citation: RRID:CVCL_1847

Description: Cell line PaTu 8988t is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Pancreatic adenocarcinoma

Defining Citation: PMID:1348891, PMID:10408907, PMID:10700188, PMID:11668190, PMID:15126341, PMID:15688027, PMID:20215515, PMID:22460905, PMID:22585861, PMID:25167228, PMID:25485619, PMID:25877200, PMID:26216984, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29444439, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: PaTu 8988t

Synonyms: PA-TU-8988T, PaTu8988t, PaTu8988T, PATU8988T, PaTu 8988 T, PaTu-8988t, PATU-8988T, PATU-T, PA-TU T, 8988T, PaCL4

Cross References: BTO:BTO_0005878, CLO:CLO_0008384, EFO:EFO_0005713, CLDB:cl3862, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:986,

BioSample:SAMN03473157, BioSample:SAMN10988386, cancercelllines:CVCL_1847, Cell_Model_Passport:SIDM00453, ChEMBL-Cells:CHEMBL4295420, ChEMBL-Targets:CHEMBL4296488, CLS:305133, Cosmic:873006, Cosmic:948382, Cosmic:1524020, Cosmic:1995611, Cosmic:2046531, Cosmic:2434111, Cosmic-CLP:1240201, DepMap:ACH-000023, DSMZ:ACC-162, DSMZCellDive:ACC-162, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS158AAA, GDSC:1240201, GEO:GSM206535, GEO:GSM385524, GEO:GSM385535, GEO:GSM816667, GEO:GSM827178, GEO:GSM887504, GEO:GSM888586, GEO:GSM16703371, IGRhCellID:PA-TU-8988T%20GEO, LiGeA:CCLE_005, LINCS_LDP:LCL-1746, PharmacoDB:PATU8988T_1238_2019, PRIDE:PXD030304, Progenetix:CVCL_1847, PubChem_Cell_line:CVCL_1847, Wikidata:Q54938330

ID: CVCL_1847

Record Creation Time: 20220427T221412+0000

Record Last Update: 20260829T235552+0000

Ratings and Alerts

No rating or validation information has been found for PaTu 8988t.

No alerts have been found for PaTu 8988t.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 52 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Pan Z, et al. (2026) OCIAD2-IQGAP1 interaction promotes pancreatic cancer progression by suppressing oxidative stress and mitochondria-mediated apoptosis. Cellular signalling, 138, 112217.

Zhang H, et al. (2026) Combining ferroptosis inducers with gemcitabine to enhance treatment efficacy in pancreatic cancer. Cancer & metabolism, 14(1).

Gong D, et al. (2026) GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Cell reports, 45(5), 117314.

Ge X, et al. (2026) PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. Cancer research, 86(15), 3819.

Zhou X, et al. (2026) DPP4 suppresses pancreatic cancer growth by enhancing ferroptosis sensitivity through stabilization of ACSL4. Cellular signalling, 143, 112446.

Zhang J, et al. (2026) Hui-Xiang Decoction Against Pancreatic Cancer by Regulating AKT and Activating the Hippo Signaling Pathway. Chemistry & biodiversity, 23(5), e02356.

Assi M, et al. (2026) Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. Cell, 189(6), 1731.

Zhang T, et al. (2026) A Metal-Free Carbon Monoxide Prodrug Suppresses Metastasis of Pancreatic and Breast Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(29), e19898.

Woo SM, et al. (2026) Inhibiting Fatty Acid Oxidation Reverses Autophagy-Mediated Acquired Chemotherapy Resistance in Pancreatic Ductal Adenocarcinoma. Cancer research, 86(13), 3194.

Murchison AK, et al. (2026) Mitochondrial degradation of metallothionein enables local zinc mobilization during zinc limitation. bioRxiv : the preprint server for biology.

Zhao B, et al. (2025) PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma. Cell reports, 44(4), 115541.

Wang S, et al. (2025) IFN-??-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Nature communications, 16(1), 10733.

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Nature communications, 16(1), 4866.

Cunniff PJ, et al. (2025) KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. Nature communications, 16(1), 9996.

Wittenzellner K, et al. (2025) Label-free single-cell phenotyping to determine tumor cell heterogeneity in pancreatic cancer in real time. JCI insight, 10(13).

Xiong Z, et al. (2025) A novel defined manganese metabolism-related gene signature for predicting the prognosis of pancreatic ductal adenocarcinoma. Oncology letters, 30(3), 436.

Jain A, et al. (2025) Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. Science (New York, N.Y.), 387(6741), eadq8331.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. iScience, 28(2), 111842.

Gong D, et al. (2025) Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. Science advances, 11(42), eadx0632.

Bhattacharyya S, et al. (2024) Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. Nature cancer, 5(2), 283.